1. Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region
- Author
-
Leen Oyoun Alsoud, Khalid Almuti, Wasim S El Nekidy, Mohamed AlJaabari, Wael Al Mahmeed, Bassam Atallah, and Zohour Anouassi
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Time Factors ,United Arab Emirates ,Hemorrhage ,Inappropriate Prescribing ,030204 cardiovascular system & hematology ,Logistic regression ,Risk Assessment ,Dabigatran ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Drug Dosage Calculations ,Dosing ,Practice Patterns, Physicians' ,Stroke ,Aged ,Retrospective Studies ,Pharmacology ,Aged, 80 and over ,Rivaroxaban ,Embolic Stroke ,business.industry ,Atrial fibrillation ,Middle Aged ,medicine.disease ,Drug Utilization ,030104 developmental biology ,Cross-Sectional Studies ,Treatment Outcome ,Health Care Surveys ,Apixaban ,Female ,Cardiology and Cardiovascular Medicine ,business ,Major bleeding ,medicine.drug ,Factor Xa Inhibitors - Abstract
Direct oral anticoagulants (DOACs) have proven efficacy to prevent cardioembolic strokes. Data are scarce about the appropriateness of DOAC dosing in the Middle East. We investigated the prevalence of inappropriate DOAC dosing in the region. A cross-sectional study was conducted at our hospital between April 2015 and February 2019 of patients receiving 1 of the 3 available DOACs. Patients with incomplete data sets, those prescribed DOACs for indications other than atrial fibrillation, on DOACs for
- Published
- 2020